1 mL BAC
5 units
resulting U-100 draw
- Concentration
- 1 mg/mL
- BAC added
- 1 mL
SinglePreclinicalPreclinicalVery Low confidenceSourced
IGF-1 LR3
A long-acting IGF-1 research analogue used mainly in laboratory models. Clinical evidence for approved recombinant human IGF-1 does not transfer to LR3.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community-provenance subcutaneous line from forum logs - clustering at 50 mcg around training in short 20-day to 4-6 week cycles, reconstituted in acetic-acid water. Community reports only, not a validated schedule.
Reported maximum quantity
Short cycle at 50 mcg (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.Reported cycle phases
Select a point for its calculation examples- Short cycle (SubQ)50 mcgReports cluster at 50 mcg (range 50-100 mcg) subcutaneously around training in short 20-day to 4-6 week cycles; reconstituted in acetic-acid water, not bacteriostatic water. Higher doses or longer cycles are said to speed receptor downregulation.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 50 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw15 U
20-30 U reference band
2 mL BAC
10 units
resulting U-100 draw
- Concentration
- 0.5 mg/mL
- BAC added
- 2 mL
3 mL BAC
15 units
resulting U-100 draw
- Concentration
- 0.333 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 1 mg research vial
20 mcg daily in weeks 1-2, 40 mcg in weeks 3-4 and 50 mcg in weeks 5-8
No controlled human LR3 study validates this schedule. Evidence for authorised mecasermin or native IGF-1 is not molecularly interchangeable.
View sourceCommunity GuideSubcutaneous in reportsDaily during short self-experiments
online research community self-experiments
The best-documented archive experiment used 50 mcg subcutaneously once daily for two weeks, while another used 100 mcg daily for about one month
These are uncontrolled N-of-1 experiments, not human dose-finding evidence. A lipid-marker interpretation from the first experiment was later withdrawn by its author; raw/discussions/disc-lipid-management.md:2704-2707, 3427-3461 and 4013-4017.
View sourceCommunity GuideSubcutaneous in reportsDaily in short cycles; some 5 days on and 2 off
authenticated research-forum (Peppys) self-experiments
Subcutaneous quantities converge tightly on 50 mcg daily (reported range 50-100 mcg), dosed around training in short cycles of about 20 days to 4-6 weeks, with some running five days on and two off; the most-repeated preparation note is to reconstitute in acetic-acid water rather than bacteriostatic water to preserve potency
Forum provenance from an authenticated archive with usernames omitted. Members warn that higher doses and longer durations speed receptor downregulation, so quantities and cycles are kept low and short; reports note extreme on-cycle fatigue and one cardiac-event anecdote. Community provenance, not controlled human dose finding; the subcutaneous route and acetic-acid preparation are preserved rather than interconverted.
View sourceEvidence summary
A long-acting IGF-1 research analogue used mainly in laboratory models. Clinical evidence for approved recombinant human IGF-1 does not transfer to LR3.
Protocol basis
The protocol boundary is molecular identity. Evidence from mecasermin labels or native IGF-1 cannot be used to manufacture a human LR3 schedule.
Community provenance (Peppys)
An authenticated research-forum archive records subcutaneous self-experiments converging tightly on 50 mcg daily, within a 50-100 mcg range, dosed around training in short cycles of roughly 20 days to four to six weeks. The most-repeated preparation note is to reconstitute IGF-1 LR3 in acetic-acid water rather than bacteriostatic water to preserve potency, and members warn that higher doses or longer durations speed receptor downregulation, keeping quantities low and cycles short. Reports note extreme on-cycle fatigue and one cardiac-event anecdote; usernames are omitted and figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.
What remains uncertain
Human pharmacokinetics, safety, dose-response, long-term growth effects and clinical benefit are unknown.
Warnings and contraindications
IGF-1 LR3 is not the same molecule as authorised mecasermin.
No controlled human LR3 administration protocol was identified.
IGF signalling can affect glucose, tissue growth and multiple organ systems.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.